Neuren Pharmaceuticals is a biotechnology business based in Australia. Neuren Pharmaceuticals shares (NEU) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Neuren Pharmaceuticals has a trailing 12-month revenue of around $78.3 million. If you're looking to buy shares, check out the steps below.
Our top pick for
Low costs
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $6.72 - $15.53 |
|---|---|
| 50-day moving average | $12.03 |
| 200-day moving average | $12.2243 |
| Target price | $20.02 |
| PE ratio | 34.21 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.44 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$15.04
| 1 week (2023-11-22) | -0.46% |
|---|---|
| 1 month (2023-10-30) | 44.20% |
| 3 months (2023-08-30) | 16.14% |
| 6 months (2023-05-30) | 9.78% |
| 1 year (2022-11-30) | 88.00% |
|---|---|
| 2 years (2021-11-30) | 735.56% |
| 3 years (2020-11-30) | 1,142.98% |
| 5 years (2018-11-30) | 989.86% |
Valuing Neuren Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neuren Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neuren Pharmaceuticals 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Neuren Pharmaceuticals shares trade at around 34x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Neuren Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $54.8 million (£0.0 million).
The EBITDA is a measure of a Neuren Pharmaceuticals 's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $78.3 million |
|---|---|
| Operating margin TTM | 76.51% |
| Gross profit TTM | $2.7 million |
| Return on assets TTM | 51.8% |
| Return on equity TTM | 88.06% |
| Profit margin | 70.26% |
| Book value | 0.723 |
| Market capitalisation | $1.9 billion |
TTM: trailing 12 months
We're not expecting Neuren Pharmaceuticals to pay a dividend over the next 12 months.
Neuren Pharmaceuticals 's shares were split on a 1:20 basis on 21 November 2017. So if you had owned 20 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Neuren Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Neuren Pharmaceuticals shares which in turn could have impacted Neuren Pharmaceuticals 's share price.
Over the last 12 months, Neuren Pharmaceuticals 's shares have ranged in value from as little as $6.72 up to $15.53. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Neuren Pharmaceuticals 's is 1.601. This would suggest that Neuren Pharmaceuticals 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
